LIVIVO - Search results -

Search results

Result 1 - 10 of total 275

Search options

Article ; Online: The role of trabectedin as second-line treatment of advanced soft tissue sarcoma: update of key efficacy and safety data.

Le Cesne, Axel

2022 Volume 18, Issue 30s, Page(s) 1–3

MeSH term(s)	Humans ; Trabectedin/adverse effects ; Soft Tissue Neoplasms/drug therapy ; Sarcoma/drug therapy ; Antineoplastic Agents, Alkylating/adverse effects ; Dioxoles/adverse effects
Chemical Substances	Trabectedin (ID0YZQ2TCP) ; Antineoplastic Agents, Alkylating ; Dioxoles
Language	English
Publishing date	2022-10-06
Publishing country	England
Document type	Journal Article
ZDB-ID	2274956-1
ISSN	1744-8301 ; 1479-6694
ISSN (online)	1744-8301
ISSN	1479-6694
DOI	10.2217/fon-2022-0516
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6478: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: UGT1A1 Testing in Breast Cancer: should it become routine practice in patients treated with antibody-drug conjugates?

Ibrahim, Rebecca / Khoury, Rita / Ibrahim, Tony / Le Cesne, Axel / Assi, Tarek

Critical reviews in oncology/hematology

2024 Volume 196, Page(s) 104265

Abstract: The use of genetic testing to personalize therapeutic strategies in cancer is rapidly evolving and thus changing the landscape of treatment of oncologic patients. The UGT1A1 gene is an important component for the metabolism and glucoronidation of certain ...

Abstract	The use of genetic testing to personalize therapeutic strategies in cancer is rapidly evolving and thus changing the landscape of treatment of oncologic patients. The UGT1A1 gene is an important component for the metabolism and glucoronidation of certain drugs, including irinotecan and sacituzumab govitecan (SG); therefore, various UGT1A1 polymorphisms leading to decreased function of the UGT1A1 enzyme may lead to increased risk of treatment-related side effects. Testing for UGT1A1 polymorphism is not routinely adopted in clinical practice; that is due to the lack of concise studies and recommendations concerning the clinical relevance of this test and its impact on the quality of life of cancer patients. The knowledge regarding UGT1A1 polymorphism and its clinical relevance will be reviewed in this article, as well as the published literature on the association between UGT1A1 polymorphism and the toxicity risk of irinotecan as well as sacituzumab govitecan. The current recommendations and guidelines on UGT1A1 testing will be discussed in detail in the hopes of providing guidance to oncologists in their clinical practice.
MeSH term(s)	Humans ; Female ; Irinotecan ; Breast Neoplasms/drug therapy ; Breast Neoplasms/genetics ; Breast Neoplasms/chemically induced ; Quality of Life ; Camptothecin/adverse effects ; Immunoconjugates/adverse effects ; Genotype ; Glucuronosyltransferase
Chemical Substances	Irinotecan (7673326042) ; UGT1A1 enzyme (EC 2.4.1.-) ; Camptothecin (XT3Z54Z28A) ; Immunoconjugates ; Glucuronosyltransferase (EC 2.4.1.17)
Language	English
Publishing date	2024-02-01
Publishing country	Netherlands
Document type	Journal Article ; Review
ZDB-ID	605680-5
ISSN	1879-0461 ; 0737-9587 ; 1040-8428
ISSN (online)	1879-0461
ISSN	0737-9587 ; 1040-8428
DOI	10.1016/j.critrevonc.2024.104265
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1931: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A review of the efficacy of trabectedin as second-line treatment of advanced soft tissue sarcoma.

Le Cesne, Axel / Martín-Broto, Javier / Grignani, Giovanni

Future oncology (London, England)

2022 Volume 18, Issue 30s, Page(s) 5–11

Abstract: The goal of second-line therapy for most patients with advanced soft tissue sarcoma is long-term tumor control without detriment to quality of life. Clinical practice guidelines recommend trabectedin as a second-line option for advanced soft tissue ... ...

Abstract	The goal of second-line therapy for most patients with advanced soft tissue sarcoma is long-term tumor control without detriment to quality of life. Clinical practice guidelines recommend trabectedin as a second-line option for advanced soft tissue sarcoma as it can provide the necessary balance between these interwoven goals. Cumulative experience with trabectedin in clinical trials and clinical practice has informed its usage such that greater benefit can be derived. In particular, use in earlier lines allows more patients to achieve prolonged tumor control (six or more cycles). Efficacy outcomes are superior when trabectedin is administered as second- versus later-line therapy and when it is used continuously until disease progression.
MeSH term(s)	Humans ; Antineoplastic Agents, Alkylating ; Dioxoles ; Quality of Life ; Sarcoma/drug therapy ; Sarcoma/pathology ; Soft Tissue Neoplasms/drug therapy ; Tetrahydroisoquinolines ; Trabectedin/therapeutic use
Chemical Substances	Antineoplastic Agents, Alkylating ; Dioxoles ; Tetrahydroisoquinolines ; Trabectedin (ID0YZQ2TCP)
Language	English
Publishing date	2022-10-06
Publishing country	England
Document type	Review ; Journal Article
ZDB-ID	2274956-1
ISSN	1744-8301 ; 1479-6694
ISSN (online)	1744-8301
ISSN	1479-6694
DOI	10.2217/fon-2022-0517
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6478: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Trabectedin as second-line treatment in advanced soft tissue sarcoma: quality of life and safety outcomes.

Grignani, Giovanni / Le Cesne, Axel / Martín-Broto, Javier

Future oncology (London, England)

2022 Volume 18, Issue 30s, Page(s) 13–22

Abstract: The choice of second- and later-line options for advanced soft tissue sarcoma (aSTS) should always be considered from the patient's perspective, taking into account the potential impact of treatment on daily activities and quality of life. This review ... ...

Abstract	The choice of second- and later-line options for advanced soft tissue sarcoma (aSTS) should always be considered from the patient's perspective, taking into account the potential impact of treatment on daily activities and quality of life. This review examines data on the safety of trabectedin in the management of patients with aSTS as reported in clinical trials and real-world studies. Evidence indicates that trabectedin exhibits an acceptable and manageable safety profile and is compatible with daily activities. Trabectedin is associated with low rates of toxicity-related discontinuations, few potentially life-threatening toxicities, a lack of apparent cumulative toxicities and low rates of grade 3/4 nausea, vomiting and fatigue. Trabectedin represents a valuable second-line option for aSTS, including in elderly patients.
MeSH term(s)	Humans ; Aged ; Trabectedin/adverse effects ; Quality of Life ; Tetrahydroisoquinolines/adverse effects ; Dioxoles/adverse effects ; Antineoplastic Agents, Alkylating/adverse effects ; Soft Tissue Neoplasms/drug therapy ; Sarcoma/drug therapy
Chemical Substances	Trabectedin (ID0YZQ2TCP) ; Tetrahydroisoquinolines ; Dioxoles ; Antineoplastic Agents, Alkylating
Language	English
Publishing date	2022-10-06
Publishing country	England
Document type	Review ; Journal Article
ZDB-ID	2274956-1
ISSN	1744-8301 ; 1479-6694
ISSN (online)	1744-8301
ISSN	1479-6694
DOI	10.2217/fon-2022-0518
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6478: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Making the Best of Available Options for Optimal Sarcoma Treatment.

Le Cesne, Axel

Oncology

2018 Volume 95 Suppl 1, Page(s) 11–20

Abstract: For 35 years options for treating advanced soft tissue sarcoma (STS) were limited to doxorubicin, dacarbazine and ifosfamide. In 2007, trabectedin was approved. Since then, several other agents have become available and many more are in development, ... ...

Abstract	For 35 years options for treating advanced soft tissue sarcoma (STS) were limited to doxorubicin, dacarbazine and ifosfamide. In 2007, trabectedin was approved. Since then, several other agents have become available and many more are in development, ushering in a new era in disease management. Considerable scope exists for improving outcomes of advanced STS through better trial design and improved patient care in everyday practice. After anthracycline failure, there are a range of treatment options and, increasingly, the choice of therapy is histology driven. Introduction of newer agents and optimising use of established agents such as trabectedin has led to an increase in overall survival of advanced STS patients. Optimising treatment with trabectedin is being achieved through more extensive experience in drug management, mainly associated with use in earlier lines and uninterrupted use until disease progression. Identification by next-generation sequencing of a significant proportion of cases of actionable mutations among patients with advanced STS suggests a move towards matched therapy in future. As the armamentarium of active agents in advanced sarcoma increases, so too will the challenge of selecting the right drug for the right patient at the right time, in accordance with the patient's lifestyle and wishes.
MeSH term(s)	Antineoplastic Agents, Alkylating/therapeutic use ; Biomarkers, Tumor ; Clinical Trials as Topic ; Disease Management ; High-Throughput Nucleotide Sequencing ; Humans ; Practice Guidelines as Topic ; Sarcoma/drug therapy ; Trabectedin/therapeutic use
Chemical Substances	Antineoplastic Agents, Alkylating ; Biomarkers, Tumor ; Trabectedin (ID0YZQ2TCP)
Language	English
Publishing date	2018-12-14
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	250101-6
ISSN	1423-0232 ; 0030-2414
ISSN (online)	1423-0232
ISSN	0030-2414
DOI	10.1159/000494861
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh III Zs.151: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Overview of the role of liquid biopsy in cancer management.

Assi, Tarek / Khoury, Rita / Ibrahim, Rebecca / Baz, Maria / Ibrahim, Tony / LE Cesne, Axel

Translational oncology

2023 Volume 34, Page(s) 101702

Abstract: With the emergence of novel targeted therapeutic options in early-stage and advanced-stage malignancies, researchers have shifted their focus on developing personalized treatment plans through molecular profiling. Circulating tumor DNA (ctDNA) is a cell- ... ...

Abstract	With the emergence of novel targeted therapeutic options in early-stage and advanced-stage malignancies, researchers have shifted their focus on developing personalized treatment plans through molecular profiling. Circulating tumor DNA (ctDNA) is a cell-free DNA (ctDNA) fragment, originating from tumor cells, and circulating in the bloodstream as well as biological fluids. Over the past decade, many techniques were developed for liquid biopsies through next-generation sequencing. This alternative non-invasive biopsy offers several advantages in various types of tumors over traditional tissue biopsy. The process of liquid biopsy is considered minimally invasive and therefore easily repeatable when needed, providing a more dynamic analysis of the tumor cells. Moreover, it has an advantage in patients with tumors that are not candidates for tissue sampling. Besides, it offers a deeper understanding of tumor burden as well as treatment response, thereby enhancing the detection of minimal residual disease and therapeutic guidance for personalized medicine. Despite its many advantages, ctDNA and liquid biopsy do have some limitations. This paper discusses the basis of ctDNA and the current data available on the subject, as well as its clinical utility. We also reflect on the limitations of using ctDNA in addition to its future perspectives in clinical oncology and precision medicine.
Language	English
Publishing date	2023-05-31
Publishing country	United States
Document type	Journal Article
ZDB-ID	2443840-6
ISSN	1936-5233
ISSN	1936-5233
DOI	10.1016/j.tranon.2023.101702
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: A Comprehensive Review on the Role of Lurbinectedin in Soft Tissue Sarcomas.

Khoury, Rita / Assi, Tarek / Ibrahim, Rebecca / Ibrahim, Tony / Verret, Benjamin / Henon, Clemence / Bahleda, Ratislav / Le Cesne, Axel

Current treatment options in oncology

2024 Volume 25, Issue 2, Page(s) 176–190

Abstract: Opinion statement: Soft tissue sarcoma (STS), a substantial group of aggressive and rare tumors with tissue heterogeneity, is infrequently represented in clinical trials with an urgent necessity for newer treatment options. Lurbinectedin, an analog of ... ...

Abstract	Opinion statement: Soft tissue sarcoma (STS), a substantial group of aggressive and rare tumors with tissue heterogeneity, is infrequently represented in clinical trials with an urgent necessity for newer treatment options. Lurbinectedin, an analog of trabectedin, is currently approved, in various countries, as a single agent, for the treatment of patients with relapsed small cell lung cancer (SCLC). However, preclinical and phase I and phase II trials have demonstrated the efficacy of lurbinectedin in different tumor types, including STS. The better understanding of the pathophysiology and evolution of STS as well as the mechanism of action of lurbinectedin in addition to the available data regarding the activity of this drug in this subset of patients will pave the way to newer therapeutic options and strategies.
MeSH term(s)	Humans ; Tetrahydroisoquinolines/therapeutic use ; Tetrahydroisoquinolines/pharmacology ; Antineoplastic Agents, Alkylating/therapeutic use ; Antineoplastic Agents, Alkylating/pharmacology ; Dioxoles/therapeutic use ; Dioxoles/pharmacology ; Neoplasm Recurrence, Local/drug therapy ; Sarcoma/drug therapy ; Sarcoma/pathology ; Soft Tissue Neoplasms/drug therapy ; Carbolines ; Heterocyclic Compounds, 4 or More Rings
Chemical Substances	PM 01183 ; Tetrahydroisoquinolines ; Antineoplastic Agents, Alkylating ; Dioxoles ; Carbolines ; Heterocyclic Compounds, 4 or More Rings
Language	English
Publishing date	2024-02-07
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2057351-0
ISSN	1534-6277 ; 1527-2729
ISSN (online)	1534-6277
ISSN	1527-2729
DOI	10.1007/s11864-024-01178-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5523: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The current reality of soft tissue sarcomas: advances, controversies, areas for improvement, and promising new treatments.

Blay, Jean-Yves / Le Cesne, Axel / Demetri, George D

Expert review of anticancer therapy

2020 Volume 20, Issue sup1, Page(s) 29–39

Abstract: ... ...

Abstract	Introduction
MeSH term(s)	Animals ; Humans ; Molecular Targeted Therapy ; Oncogenes ; Sarcoma/genetics ; Sarcoma/pathology ; Sarcoma/therapy ; Soft Tissue Neoplasms/genetics ; Soft Tissue Neoplasms/pathology ; Soft Tissue Neoplasms/therapy
Language	English
Publishing date	2020-04-29
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	2112544-2
ISSN	1744-8328 ; 1473-7140
ISSN (online)	1744-8328
ISSN	1473-7140
DOI	10.1080/14737140.2020.1753511
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5907: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Making the Best of Available Options for Optimal Sarcoma Treatment

Le Cesne, Axel

Oncology

2018 Volume 95, Issue Suppl 1, Page(s) 11–20

Institution	Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
Abstract	For 35 years options for treating advanced soft tissue sarcoma (STS) were limited to doxorubicin, dacarbazine and ifosfamide. In 2007, trabectedin was approved. Since then, several other agents have become available and many more are in development, ushering in a new era in disease management. Considerable scope exists for improving outcomes of advanced STS through better trial design and improved patient care in everyday practice. After anthracycline failure, there are a range of treatment options and, increasingly, the choice of therapy is histology driven. Introduction of newer agents and optimising use of established agents such as trabectedin has led to an increase in overall survival of advanced STS patients. Optimising treatment with trabectedin is being achieved through more extensive experience in drug management, mainly associated with use in earlier lines and uninterrupted use until disease progression. Identification by next-generation sequencing of a significant proportion of cases of actionable mutations among patients with advanced STS suggests a move towards matched therapy in future. As the armamentarium of active agents in advanced sarcoma increases, so too will the challenge of selecting the right drug for the right patient at the right time, in accordance with the patient’s lifestyle and wishes.
Keywords	Treatment optimization ; Advanced soft tissue sarcoma ; Next-generation sequencing ; Trabectedin
Language	English
Publishing date	2018-12-14
Publisher	S. Karger AG
Publishing place	Basel, Switzerland
Document type	Article
Note	Review
ZDB-ID	250101-6
ISSN	1423-0232 ; 0030-2414
ISSN (online)	1423-0232
ISSN	0030-2414
DOI	10.1159/000494861
Database	Karger publisher's database

In stock of ZB MED Cologne/Königswinter

Uh III Zs.151: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Experience with second-line trabectedin in daily clinical practice: case studies.

Martín-Broto, Javier / Hindi, Nadia / Grignani, Giovanni / Merlini, Alessandra / Ibrahim, Tony / Le Cesne, Axel

Future oncology (London, England)

2022 Volume 18, Issue 30s, Page(s) 23–32

Abstract: As a recommended second-line option for advanced soft tissue sarcoma, trabectedin can provide the necessary balance between long-term tumor control and preserved quality of life. Three case studies illustrate the long-lasting responses that patients can ... ...

Abstract	As a recommended second-line option for advanced soft tissue sarcoma, trabectedin can provide the necessary balance between long-term tumor control and preserved quality of life. Three case studies illustrate the long-lasting responses that patients can achieve with second-line trabectedin. A female patient with metastatic leiomyosarcoma maintained disease control for 2 years with trabectedin (× 41 cycles) with excellent tolerability and no relevant adverse events. At the time of writing, a male patient with a metastatic solitary fibrous tumor was asymptomatic after 30 cycles of trabectedin and treatment was ongoing. A young male patient with a recurrent, nonresectable, retroperitoneal myxoid/round cell liposarcoma was able to continue his sporting activities (triathlons) over 2 years with trabectedin (× 14 cycles) plus watchful waiting.
MeSH term(s)	Humans ; Male ; Female ; Adult ; Trabectedin/adverse effects ; Quality of Life ; Antineoplastic Agents, Alkylating/adverse effects ; Neoplasm Recurrence, Local/drug therapy ; Sarcoma/drug therapy ; Liposarcoma/drug therapy ; Tetrahydroisoquinolines/adverse effects ; Dioxoles/adverse effects
Chemical Substances	Trabectedin (ID0YZQ2TCP) ; Antineoplastic Agents, Alkylating ; Tetrahydroisoquinolines ; Dioxoles
Language	English
Publishing date	2022-10-06
Publishing country	England
Document type	Journal Article
ZDB-ID	2274956-1
ISSN	1744-8301 ; 1479-6694
ISSN (online)	1744-8301
ISSN	1479-6694
DOI	10.2217/fon-2022-0519
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6478: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito